Riskpilot← Back to searchSign inGet full accessLimedic Aktiebolag
ABActiveOrg 5564978921Hägernäsvägen 10Wholesale of pharmaceutical and medical goods · NACE 4646Est. 19941-4 employees
Revenue 2024
SEK 33,3M
+10% vs 2023
EBITDA margin
4.4%
-29% vs 2023
Equity ratio
6.4%
Financial strength
Net profit 2024
SEK 722K
-32% vs 2023
| Revenue | SEK 33,3M | +10% |
| EBITDA | SEK 1,5M | -29% |
| Net profit | SEK 722K | -32% |
| Total assets | SEK 23,2M | +5% |
| Equity | SEK 1,5M | -26% |
| Employees | — | — |
Legal name
Limedic Aktiebolag
Org number
5564978921
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
28 oktober 1994
Share capital
SEK 250 000
Employees
1-4
VAT registered
Yes
Audit selected
No
Last report
2024-08-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas ensam av Andersen, Jan Tore Anders
Company purpose
Bolaget skall bedriva import, export och försäljning av medicinsk utrustning, utveckling av produkter och tjänster inom medicin, fastighetsförvaltning och därmed förenlig verksamhet.
Address
Hägernäsvägen 10
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | 26 756 | 25 494 | 24 771 | 23 444 | 26 298 | 30 316 | 33 303 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | 340 | 409 | 629 | 514 | 304 | 1 025 | 1 663 | 2 589 | 2 083 | 1 476 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −6 | −7 | −7 | −7 | −257 | −131 |
| EBIT | 340 | 409 | 629 | 514 | 298 | 1 018 | 1 656 | 2 582 | 1 826 | 1 345 |
| Net financials | 6 | 5 | — | −4 | −3 | — | −536 | −11 | 18 | 1 |
| Profit before tax | 584 | 602 | 575 | 648 | 375 | 2 462 | 1 387 | 2 572 | 1 444 | 1 046 |
| Tax | −174 | −160 | −158 | −174 | −131 | −570 | −399 | −640 | −383 | −324 |
| Net profit | 410 | 442 | 417 | 474 | 244 | 1 892 | 988 | 1 932 | 1 061 | 722 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 14 651 | 20 364 | 21 463 | 28 610 | 21 005 | 21 269 | 20 692 | 20 294 | 22 076 | 23 242 |
| Equity | 2 160 | 2 602 | 3 019 | 3 493 | 3 737 | 5 629 | 1 288 | 2 232 | 2 004 | 1 476 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 10 695 | 16 154 | 16 782 | 23 593 | 15 824 | 15 641 | 19 404 | 18 062 | 19 673 | 21 066 |
| Total debt | 10 695 | 16 154 | 16 782 | 23 593 | 15 824 | 15 641 | 19 404 | 18 062 | 19 673 | 21 066 |
EBITDA margin
4.4%
This company
15.8%
Market median
-72% vs market
20152024
Equity ratio
6.4%
This company
38.2%
Market median
-83% vs market
20152024
Return on equity
48.9%
This company
18.4%
Market median
+166% vs market
20152024
Net profit margin
2.2%
This company
8.1%
Market median
-73% vs market
20152024
Asset turnover
1.43×
This company
1.12×
Market median
+28% vs market
20152024
Debt / equity
14.75×
This company
0.62×
Market median
-2279% vs market
20152024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-09-01 – 2024-08-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-09-01 – 2023-08-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-09-01 – 2022-08-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-09-01 – 2021-08-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2019-09-01 – 2020-08-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2018-09-01 – 2019-08-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2017-09-01 – 2018-08-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2016-09-01 – 2017-08-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2015-09-01 – 2016-08-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2014-09-01 – 2015-08-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
EC Audit | Audit | 2025 | — | — |
TN Audit | Audit | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2022 | — | — | |
| Board of Directors | 2022 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Arkley Holding AB | Company | 51.0% | 51.0% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Arkley Holding AB
Limedic Aktiebolag Board members of Limedic Aktiebolag also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Eva Camilla Beijron | Audit | 0 companies |
| Tomas Nöjd | Audit | 0 companies |
| Mats Henrik Forsman | Deputy Board Member | 0 companies |
| Jan Tore Anders Andersen | Board of Directors | 0 companies |